Arcus Biosciences Q2 2024 GAAP EPS $(1.02) Beats $(1.18) Estimate, Sales $39.000M Beat $25.613M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcus Biosciences (NYSE:RCUS) reported Q2 2024 GAAP EPS of $(1.02), beating the estimate of $(1.18). Sales were $39.000M, surpassing the $25.613M estimate and showing a 34.48% increase from the same period last year.
August 08, 2024 | 8:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arcus Biosciences reported better-than-expected Q2 2024 earnings and sales, with EPS of $(1.02) beating the $(1.18) estimate and sales of $39.000M surpassing the $25.613M estimate. This indicates strong performance and growth.
The better-than-expected earnings and significant sales growth indicate strong performance, likely leading to positive investor sentiment and a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100